Business, energy, technology, markets and global industry news from Business News Today

Inflammatory Bowel Disease

PharmaDeviceNews Inflammatory Bowel Disease
WuXi Biologics and Sinorda partner on bispecific antibody SND006 for inflammatory bowel disease
Pharma & Biotech

Sinorda bets on bispecifics with WuXi Biologics for IBD and autoimmune expansion

WuXi Biologics and Sinorda Biomedicine have entered into a strategic collaboration to advance the development and clinical manufacturing of SND006, a novel bispecific antibody targeting inflammatory bowel disease and other autoimmune conditions. The agreement will see Sinorda Biomedicine utilize WuXi Biologics’ CRDMO capabilities to support preclinical development, IND-enabling activities, and global clinical supply for SND006,

Read More
Pharma & Biotech

Why Boehringer’s TL1A/IL23 bispecific bet could reshape IBD drug development

Find out why Boehringer is betting big on Simcere’s bispecific SIM0709 to challenge the IBD treatment ceiling.

Read More
Pharma & Biotech

AI in clinical operations: Can PhaseV’s real-time site optimization reshape IBD trial efficiency?

Find out how PhaseV’s AI-powered ClinOps Optimizer is changing IBD trial site selection with causal ML and real-time analytics. Read the full analysis.

Read More
Pharma & Biotech

Replacing microbiota rejuvenates aging gut tissue: What new mouse data means for regenerative GI therapies

A mouse study suggests young microbiota can rejuvenate aging gut tissue. Find out what this could mean for regenerative GI therapies and IBD care.

Read More
Pharma & Biotech

MH002 enters phase 2b: Can MRM Health’s live biotherapeutic consortium redefine ulcerative colitis treatment standards?

MRM Health's MH002 enters phase 2b for ulcerative colitis. Can this live biotherapeutic redefine immune-sparing treatment in IBD? Find out what’s at stake.

Read More
Pharma & Biotech

Enveda’s ENV-6946 enters Phase 1: Can a “multi-biologic in a pill” reshape the future of IBD therapy?

Can Enveda’s ENV-6946 deliver the efficacy of biologics in a pill for IBD? Find out why its triple-cytokine Phase 1 trial is drawing industry attention.

Read More